ES3001104T3 - Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias - Google Patents

Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias Download PDF

Info

Publication number
ES3001104T3
ES3001104T3 ES21765908T ES21765908T ES3001104T3 ES 3001104 T3 ES3001104 T3 ES 3001104T3 ES 21765908 T ES21765908 T ES 21765908T ES 21765908 T ES21765908 T ES 21765908T ES 3001104 T3 ES3001104 T3 ES 3001104T3
Authority
ES
Spain
Prior art keywords
compound
treatment
asthma
use according
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21765908T
Other languages
English (en)
Spanish (es)
Inventor
Palomino Laria Julio Castro-
Gomez Juan Camacho
Laria Nahomi Castro-Palomino
Alvarez Alina Ariosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Application granted granted Critical
Publication of ES3001104T3 publication Critical patent/ES3001104T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES21765908T 2020-08-21 2021-08-20 Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias Active ES3001104T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (1)

Publication Number Publication Date
ES3001104T3 true ES3001104T3 (es) 2025-03-04

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21765908T Active ES3001104T3 (es) 2020-08-21 2021-08-20 Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
AU2015315628A1 (en) * 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
JP2023538419A (ja) 2023-09-07
AU2021327728B2 (en) 2026-06-11
PL4199922T3 (pl) 2025-02-10
WO2022038261A1 (en) 2022-02-24
DK4199922T3 (da) 2024-11-25
CA3190081A1 (en) 2022-02-24
KR20230054444A (ko) 2023-04-24
RS66263B1 (sr) 2024-12-31
EP3957308A1 (en) 2022-02-23
BR112023002778A2 (pt) 2023-03-14
HRP20241621T1 (hr) 2025-01-31
CN115942933A (zh) 2023-04-07
SI4199922T1 (sl) 2025-03-31
US20230321053A1 (en) 2023-10-12
PT4199922T (pt) 2024-12-18
AU2021327728A1 (en) 2023-03-09
LT4199922T (lt) 2025-01-10
MX2023002156A (es) 2023-03-01
EP4199922A1 (en) 2023-06-28
EP4199922B1 (en) 2024-09-25
JP7794807B2 (ja) 2026-01-06
FI4199922T3 (fi) 2024-12-05
HUE069338T2 (hu) 2025-02-28

Similar Documents

Publication Publication Date Title
ES2645368T3 (es) Terapias para mejorar la función pulmonar
US20220152057A1 (en) Methods and compositions for treating various disorders
Krouse et al. Asthma and the unified airway
Ohta et al. Japanese guideline for adult asthma
US9815894B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
Fujimura et al. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
Howe et al. Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
ES2779762T3 (es) Tratamiento de la alopecia areata
TW202539683A (zh) 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘
Weldon Gastroesophageal reflux disease and sinusitis: Their role in patients with chronic cough.
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
EA048711B1 (ru) (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей
TW202237078A (zh) 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物
JP2022515615A (ja) 慢性炎症性腸疾患の治療のためのpar-1アンタゴニストの使用
CN119546306A (zh) 施用贝舒地尔以治疗慢性移植物抗宿主病的方法
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
WO2026007876A1 (zh) Gpr84拮抗剂的用途
HK40090654A (en) Use of dexpramipexole for the treatment of moderate to severe asthma